Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (34 quarters reported)
$178M in Q2 2014 → $32.3M now. Hover for any quarter.
As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Bicycle Therapeutics PLC | 65.4% | Unchanged | 907,032 | $21.1M |
| Bioventus, Inc | 32.3% | Unchanged | 1,488,596 | $10.4M |
| X4 Pharmaceuticals Inc | 1.6% | Unchanged | 311,490 | $532K |
| Asensus Surgical, Inc. | 0.7% | Unchanged | 510,142 | $229K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2022 · filed November 07, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Adapthealth Corp | Exited | −994,079 | −$17.9M | — |
quarter ended June 30, 2022 · filed August 12, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Adapthealth Corp | Trimmed | −296,899 | −$5.36M | 40.9% |
| Bicycle Therapeutics PLC | Trimmed | −10,186 | −$171K | 34.7% |
quarter ended March 31, 2022 · filed May 16, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Sutro Biopharma Inc | Exited | −1,824,542 | −$27.1M | — |
| Adapthealth Corp | Trimmed | −650,140 | −$10.4M | 25.0% |
| Bioventus, Inc | Trimmed | −92,435 | −$1.3M | 25.4% |
| Bicycle Therapeutics PLC | Trimmed | −936 | −$41.1K | 48.6% |
quarter ended December 31, 2021 · filed February 11, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| M Misonix, Inc. | Exited | −1,694,017 | −$42.9M | — |
| Bicycle Therapeutics PLC | Trimmed | −518,302 | −$31.5M | 36.1% |
| Bioventus, Inc | New | +1,581,031 | +$22.9M | 14.8% |
| Deciphera Pharmaceuticals Inc | Exited | −449,951 | −$15.3M | — |
| Repligen Corporation | Exited | −14,541 | −$4.2M | — |
quarter ended September 30, 2021 · filed November 15, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Adapthealth Corp | Trimmed | −970,559 | −$22.6M | 22.1% |
| Bicycle Therapeutics PLC | Trimmed | −478,818 | −$19.9M | 29.2% |
| Repligen Corporation | New | +14,541 | +$4.2M | 2.1% |
quarter ended June 30, 2021 · filed August 16, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| A Avrobio Inc | Exited | −275,034 | −$3.49M | — |
quarter ended March 31, 2021 · filed May 17, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Adapthealth Corp. | New | +2,911,677 | +$107M | 40.1% |
| American Well Corp | Exited | −1,662,646 | −$42.1M | — |
| Kalvista Pharmaceuticals Inc | Exited | −1,719,576 | −$25.7M | — |
| A Avrobio Inc | Trimmed | −916,642 | −$11.6M | 1.3% |
| Asensus Surgical, Inc. | New | +510,142 | +$1.66M | 0.6% |
| T Transenterix Inc | Exited | −510,142 | −$319K | — |
quarter ended December 31, 2020 · filed February 16, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| American Well Corp | Trimmed | −286,684 | −$7.26M | 20.3% |
| CP Catabasis Pharmaceuticals In | Exited | −285,765 | −$1.77M | — |
| A Avrobio Inc | Trimmed | −44,447 | −$620K | 8.0% |
| M Misonix, Inc. | Trimmed | −1,952 | −$24.4K | 10.2% |
Loading...
